Euro Surveill. 2016 Dec 15;21(50). pii: 30423. doi: 10.2807/1560-7917.ES.2016.21.50.30423.

Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014.

Sheppard C1, Fry NK1, Mushtaq S2, Woodford N2, Reynolds R3,4, Janes R5, Pike R2, Hill R2, Kimuli M2, Staves P2, Doumith M2, Harrison T2, Livermore DM2,6.

Author information


Conjugate vaccines have reduced pneumococcal disease in vaccinated children and unvaccinated adults, but non-vaccine serotypes are of concern, particularly if antibiotic resistant. We reviewed Streptococcus pneumoniae collected via: (i) the British Society for Antimicrobial Chemotherapy (BSAC) surveillances from 2001-2014; (ii) Public Health England's (PHE) invasive isolate surveillance from 2005-2014 and (iii) referral to PHE for resistance investigation from 2005-2014. Serotype 15A increased in all series, with many representatives showing triple resistance to macrolides, tetracyclines and penicillin. 15A was consistently among the 10 most prevalent serotypes from 2011 in PHE and BSAC invasive isolate/bacteraemia surveillance but never previously; 26-33% of these invasive 15A isolates had triple resistance. BSAC respiratory isolates were only serotyped in 2013/14 and 2014/15 (October to September); 15A was most prevalent serotype in both periods, comprising 9-11% of isolates, 38-48% of them with triple resistance. Serotype 15A represented 0-4% of S. pneumoniae referred to PHE for reference investigation annually until 2008 but rose to 29% (2013) and 32% (2014). Almost all multidrug-resistant 15A isolates were sequence type (ST) 63 variants, whereas susceptible 15A isolates were clonally diverse. The rise of serotype 15A suggests that pneumococcal conjugate vaccines will need ongoing adaptation.

This article is copyright of The Authors, 2016.


Capsular serotypes; Pneumococcal conjugate vaccine; Streptococcus pneumoniae

PMID: 28006650 DOI: 10.2807/1560-7917.ES.2016.21.50.30423

[PubMed - in process]